Pharsight

Symproic generic

Symproic is an opioid-induced constipation treatment drug owned by Bdsi. It contains the active ingredient naldemedine tosylate and was first authorized for market use on 23rd March 2017.

When will Symproic generic be available?

The generic version of Symproic is potentially releasable after 13th May 2033. This date coincides with the expiration of the last patent (US10952968) that Bdsi holds on Symproic. Furthermore, drug patent challenges against Symproic can be filed as of 23rd March 2021.

Symproic uses

Symproic, containing the active ingredient naldemedine tosylate, is primarily used for the treatment of opioid-induced constipation.

Symproic patent expiration

Symproic, an opioid-induced constipation treatment drug, holds a total of 4 patents, none of which have expired. The patent with the latest expiration date (US10952968) expires on 13th May 2033. See Symproic generic and patent details below:

Symproic dosage

Want to ask something?